Using the Dysbiosis Index to Monitor Feline IBD Treatment
Inflammatory bowel disease (IBD) in cats is a chronic gastrointestinal condition marked by persistent inflammation, altered intestinal function, and clinical signs such as vomiting, diarrhea, weight loss, or reduced appetite. Because these signs overlap with food-responsive enteropathy, infection, neoplasia, and other digestive disorders, monitoring requires more than symptom tracking alone.
The intestinal microbiome adds another layer of clinical information. Changes in bacterial communities may accompany chronic enteropathy, influence intestinal barrier function, and reflect the effects of diet, medication, and inflammation. The Dysbiosis Index (DI) provides a quantitative way to assess selected microbial changes in fecal samples.
Used alongside history, physical examination, laboratory testing, imaging, and response to treatment, the DI can help veterinary teams evaluate whether the intestinal ecosystem is moving toward a healthier pattern during feline IBD management.
What the Dysbiosis Index measures
The Dysbiosis Index is a molecular test that evaluates the relative abundance of specific bacterial groups associated with intestinal health and dysbiosis. It commonly uses quantitative polymerase chain reaction (qPCR) to measure microbial targets in feces and combines the results into a calculated score.
A score outside the laboratory’s healthy reference range suggests a disruption in the fecal microbiome. The result should be interpreted as a pattern of microbial change rather than a standalone diagnosis. A dysbiotic profile does not establish IBD, and a result within the reference range does not exclude intestinal inflammation.
The value of the test lies in repeatable measurement. When samples are collected under comparable conditions, serial DI results can show whether microbial disruption is improving, persisting, or changing during treatment.
Why microbiome monitoring matters in feline IBD
Cats with chronic enteropathy may experience shifts in microbial diversity and bacterial abundance. These changes can be associated with altered fermentation, intestinal inflammation, impaired barrier function, and changes in stool quality. However, the relationship is complex: dysbiosis may contribute to disease, result from disease, or be influenced by the interventions used to control it.
Clinical improvement and microbial improvement may also occur at different speeds. A cat may eat better and have firmer stools before the fecal microbiome has stabilized. Conversely, a DI may improve while vomiting, pain, or weight loss continues because another disease process remains active.
For that reason, the DI works best as an adjunctive biomarker. It can support a broader assessment of treatment response, help document change over time, and provide additional context when clinical signs and other findings do not align.
Building a useful monitoring plan
Before collecting a baseline sample, record the cat’s diet, recent antimicrobial or corticosteroid exposure, supplements, deworming history, and current clinical signs. These variables may influence microbial composition and can complicate comparisons between samples.
Fecal collection should follow the testing laboratory’s instructions. Ideally, clinicians use consistent sample handling and comparable timing in relation to dietary changes and medication. A baseline collected before a major intervention, followed by a planned reassessment, creates a more informative timeline than occasional testing prompted by relapse.
The interval between tests should reflect the treatment plan and clinical course. Repeating the test too soon may capture transient effects, while waiting too long can miss a meaningful change. The laboratory’s reference framework and the patient’s response should guide interpretation.
Reading results with clinical context
| Finding | Possible interpretation | Practical consideration |
|---|---|---|
| Elevated dysbiosis score at baseline | Microbial disruption is present | Assess diet, medications, inflammation, and concurrent disease |
| Lower score during treatment | The fecal microbial profile is moving toward the reference range | Compare with stool quality, appetite, body weight, and other findings |
| Persistent abnormal score | Dysbiosis may be ongoing or influenced by unresolved factors | Review adherence, recent antimicrobials, diet, and diagnostic certainty |
| Clinical improvement with little DI change | Symptoms may be responding through mechanisms not reflected in fecal microbiota | Continue comprehensive monitoring rather than escalating treatment based on the score alone |
| DI improvement with persistent clinical signs | Microbiome change may not be sufficient to control the primary disease | Reassess inflammation, food response, pain, infection, or structural disease |
A falling DI may support treatment response, but it should not be treated as a target that overrides the patient’s condition. A cat with better stool quality, stable weight, normalizing appetite, and improved comfort may be progressing appropriately even if the score remains mildly abnormal.
Likewise, a more favorable DI does not prove mucosal healing. Fecal testing reflects luminal microbial material and may not fully represent organisms attached to the intestinal mucosa or changes occurring in different gastrointestinal regions.
Factors that can alter the result
Diet is a major influence on the feline gut microbiome. A new protein source, fiber content, highly digestible formulation, or therapeutic gastrointestinal diet may change fecal bacterial profiles. The timing of sample collection should therefore be documented in relation to dietary transitions.
Antibiotics can produce substantial and sometimes prolonged changes in microbial communities. Probiotics, prebiotics, corticosteroids, immunomodulatory drugs, and antiparasitic treatments may also affect the result or the clinical signs being monitored. A single score cannot distinguish these influences from the effects of IBD itself.
Sample quality and storage are equally important. Delayed processing, contamination, or inconsistent collection can reduce the reliability of serial comparisons. Clinicians should interpret an unexpected result alongside technical comments from the laboratory and the complete patient record.
Applying DI results to treatment decisions
The DI can help organize follow-up discussions with owners. Instead of relying solely on whether diarrhea has stopped, the veterinary team can review a combination of stool consistency, vomiting frequency, appetite, body condition, weight, blood markers, imaging, and microbial trends.
Treatment decisions should still address the suspected cause and severity of disease. Nutritional management, parasite control, appropriate antimicrobial stewardship, anti-inflammatory therapy, and investigation of differential diagnoses remain central. The DI can inform the conversation, but it does not replace histopathology, endoscopy, or other diagnostic tools when those are indicated.
Veterinary professionals seeking microbiome education can explore the ActivBiome learning hub for expert-led resources on dysbiosis, chronic enteropathies, and clinical applications in dogs and cats. These materials can help place the Dysbiosis Index within the wider science of gastrointestinal health.
Practical recommendations for follow-up
- Establish a documented baseline before major changes in diet or medication whenever clinically appropriate.
- Record antimicrobial, steroid, probiotic, supplement, and deworming exposure beside each fecal sample.
- Use consistent collection, storage, and submission procedures for repeat testing.
- Interpret DI trends with clinical signs, body weight, laboratory data, imaging, and treatment adherence.
- Explain to owners that microbial recovery and symptom control may occur on different timelines.
A structured monitoring approach makes the Dysbiosis Index more useful in cats with inflammatory bowel disease. By combining serial microbiome data with careful clinical assessment, veterinary teams can track patterns, recognize confounding influences, and communicate treatment progress more clearly.
Continue developing this area of practice through the educational resources available on the site, and document participation with a course certificate when completing eligible learning activities.